LANNETT COMPANY,INC. (NYSE:LCI) Files An 8-K Regulation FD Disclosure
ITEM 7.01 REGULATION FD DISCLOSURE

On January 26, 2017, Arthur P. Bedrosian, the Chief Executive Officer of Lannett Company, Inc. (the “Company”), announced at a meeting with Forward Cody Wyoming Inc. members that Cody Laboratories, Inc., a wholly owned subsidiary of the Company, would be launching a $50 million expansion to its facilities.

The information set forth under “Item 7.01 Regulation FD Disclosure” shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as a shall be expressly set forth by specific reference in such filing.

About LANNETT COMPANY, INC. (NYSE:LCI)

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

LANNETT COMPANY, INC. (NYSE:LCI) Recent Trading Information

LANNETT COMPANY, INC. (NYSE:LCI) closed its last trading session 00.00 at 19.35 with 814,124 shares trading hands.